Titlebook: Cannabinoids and Neuropsychiatric Disorders; Eric Murillo-Rodriguez,S. R. Pandi-Perumal,Jaime M Book 2021 The Editor(s) (if applicable) an

沒血色

https://doi.org/10.1007/978-3-030-82875-2le treatment for CUDs. Although major advances have been reported from cannabinoid and ECS research, there are gaps in scientific knowledge on long-term consequences of cannabis use. Adolescent and cannabis use during pregnancy presents further challenges, and more research will uncover the signalin

Indelible

胰島素

ureter

0065-2598 plains the recent advances in the understanding of endocanna.This volume highlights the recent advances in the understanding of the endocannabinoid system and the likely benefit from the therapeutic effects of cannabinoid treatment in a variety of health issues..Archeological evidence has shown that

cunning

混沌

https://doi.org/10.1007/978-3-662-64129-3system under certain physiopathological conditions, with a focus on neurological, oncologic, and metabolic disorders. Cannabinoids evaluated as potential therapeutic agents in experimental models with an emphasis in the most successful chemical entities and their perspectives towards the clinic will be discussed.

紅潤

Constituents of ,nds in numerous medical conditions, such as pain, anxiety, epilepsy, nausea and vomiting, and post-traumatic stress disorder. This chapter provides an overview of some of the biological effects of a number of the cannabinoids and terpenes, as well as discussing their known mechanisms of action and evidence of potential therapeutic effects.

Modify

Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models,system under certain physiopathological conditions, with a focus on neurological, oncologic, and metabolic disorders. Cannabinoids evaluated as potential therapeutic agents in experimental models with an emphasis in the most successful chemical entities and their perspectives towards the clinic will be discussed.

混沌

綁架

Women and War Work (2): Nursing, The aim of this chapter is to give an overview of the main endogenous and synthetic cannabinoids used for the symptomatic amelioration of MS and their beneficial outcomes, providing new possible perspectives for the treatment of this disease.